Corcept Therapeutics Inc (CORT) Stock
Fundamentals
Source: third-party data provider, as of October 13, 2026
Compare with CORT
Recent news

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
CORT

Corcept Announces Planned Leadership Transition
Corcept Announces Planned Leadership Transition
CORT

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
CORT

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
CORT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 59.24
- MACD 12/26/9
- 2.03
- EMA 9 of MACD
- 1.61
- MACD histogram
- 0.42
- SMA 50
- $115.31
- Price above SMA 50
- EMA 50
- $111.76
- Price above EMA 50
- SMA 200
- $71.06
- Price above SMA 200
- EMA 200
- $83.12
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 12, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.17 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
CORT

Corcept Announces Planned Leadership Transition
Corcept Announces Planned Leadership Transition
CORT

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
CORT

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
CORT

Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
CORT

Corcept Grows to Mid-Cap on Institutional Support
Corcept Grows to Mid-Cap on Institutional Support
CORT

Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
CORT

Trump is up 230% on this stock trade since March
Trump is up 230% on this stock trade since March
CORT

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
CORT

Raised Guidance Lifts Corcept to 52-Week High
Raised Guidance Lifts Corcept to 52-Week High
CORT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Corcept Therapeutics Inc
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, CEO & Director | 1957 |
| Mr. Atabak Mokari | CFO & Treasurer | 1977 |
| Dr. William Guyer Pharm.D. | Chief Development Officer | 1968 |
| Mr. Gary Charles Robb J.D. | Chief Business Officer & Secretary | 1963 |
| Mr. Joseph Douglas Lyon | Chief Technology & Accounting Officer | 1978 |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer | 1960 |
| Ms. Amy Flood | Chief Human Resources & Communications Officer | — |
| Ms. Monica Tellado | President of Emerging Markets | 1973 |
| Mr. Roberto W. Vieira | President of Oncology | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 13, 2026
Technical indicators
- RSI 14
- 59.24
- MACD 12/26/9
- 2.03
- EMA 9 of MACD
- 1.61
- MACD histogram
- 0.42
- SMA 50
- $115.31
- Price above SMA 50
- EMA 50
- $111.76
- Price above EMA 50
- SMA 200
- $71.06
- Price above SMA 200
- EMA 200
- $83.12
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 12, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $50.00
- Average
- $135.25
- High
- $165.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -15.3 | +15.3 | -6.4 | |||||||||
| 2022 | -7.7 | +18.5 | -2.7 | -9.0 | -5.5 | +14.7 | +12.7 | -5.5 | -1.3 | +9.7 | -15.6 | -18.6 |
| 2023 | +13.3 | -13.0 | +9.1 | +0.1 | +3.2 | -3.1 | +15.2 | +30.9 | -17.7 | +6.8 | -9.3 | +25.1 |
| 2024 | -12.7 | +8.6 | +4.7 | -9.4 | +26.3 | +3.8 | +18.4 | -7.0 | +35.1 | +4.7 | +21.1 | -14.9 |
| 2025 | +33.9 | -9.0 | +93.4 | -21.8 | +8.5 | +2.4 | -3.1 | +1.0 | +16.4 | -12.8 | +7.1 | -56.4 |
| 2026 | +4.4 | -12.3 | +12.1 | +10.8 | +35.1 | +23.4 | +29.4 | +0.5 | +1.6 | +6.3 |



